Malignant Lymphoma Clinical Trial
Official title:
The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.
Recently, among diverse oncogenic signaling pathways, a number of studies have focused on
the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine
kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol
3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and
plays a critical role promoting malignant phenotype and has prognostic significance in
various solid cancers.
However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes
has not been performed in malignant lymphoma.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03346096 -
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma
|
Phase 2 | |
| Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
| Completed |
NCT01473095 -
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
|
Phase 1 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT02131688 -
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
|
Phase 1 | |
| Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
| Completed |
NCT00685997 -
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
|
N/A | |
| Not yet recruiting |
NCT06358001 -
EchoTip AcuCore Post-Market Clinical Study
|
||
| Recruiting |
NCT04986293 -
CPAP or BiPAP for Motion Mitigation During Radiotherapy
|
N/A | |
| Completed |
NCT01588548 -
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT04464889 -
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Completed |
NCT03316144 -
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
|
Phase 1 | |
| Terminated |
NCT01016795 -
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
|
Phase 2 | |
| Completed |
NCT04464590 -
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
|
||
| Recruiting |
NCT04698616 -
Lean Body Mass and Side Effects in Patients With Lymphoma
|
||
| Active, not recruiting |
NCT02678299 -
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT05827341 -
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
|
||
| Active, not recruiting |
NCT05515029 -
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
|
Phase 3 | |
| Not yet recruiting |
NCT05545202 -
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
|
Phase 4 |